title: Hypertriglyceridemia: the importance of identifying patients at risk.
abstract: This review aims to explain risk factors, consequences, and management strategies recommended for patients with hypertriglyceridemia. A search of PubMed was performed: 'Hypertriglyceridemia'[Majr], limited to English-language and published in the 5 years up to April 2016. Abstracts of the 680 results were screened for inclusion. Reference lists of publications included were also screened for inclusion. Approximately 25% of the United States population has elevated (≥150 mg/dL) triglycerides (TG) putting them at an increased risk of cardiovascular disease, non-alcoholic fatty liver disease, and pancreatitis. Risk factors for hypertriglyceridemia include genetics, lifestyle and diet, renal disease, endocrine disorders, and certain medications. Guidelines recommend that all patients with hypertriglyceridemia are advised on lifestyle modification to reduce TG to <150 mg/dL; a reduction in body weight of 5-10% can reduce TG by approximately 20%. For patients with TG <400 mg/dL, the primary goal is to reduce low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol, with most guidelines recommending statin therapy. When TG is ≥500 mg/dL the primary goal is to reduce TG levels to lower the risk of pancreatitis. Statin therapy (if LDL-C is elevated) in combination with a fibrate, or long-chain omega-3 fatty acid may be required. The Food and Drug Administration withdrew approval for niacin and some fibrates in combination with statins in April 2016 citing unfavorable benefit-risk profiles. With the increasing incidence of associated conditions (e.g. obesity, metabolic syndrome, and type 2 diabetes mellitus), it is likely that primary care physicians will encounter more patients with hypertriglyceridemia.
authors.affiliation: a Univeristy of California , Irvine and Kushner Wellness Center , Los Alamitos , CA , USA.
authors.forename: Pamela A
authors.initials: PA
authors.lastname: Kushner
authors.affiliation: b Canyon Medical Center , Sandy , UT , USA.
authors.forename: Michael E
authors.initials: ME
authors.lastname: Cobble
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D015228:Hypertriglyceridemia / Q000188:drug therapy / Q000453:epidemiology* / Q000503:physiopathology*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008019:Life Style; D065626:Non-alcoholic Fatty Liver Disease / Q000453:epidemiology; D010195:Pancreatitis / Q000453:epidemiology; D044469:Racial Groups; D051437:Renal Insufficiency / Q000453:epidemiology; D012307:Risk Factors; D015431:Weight Loss
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents
keywords: Coronary artery disease; diabetes; hypertriglyceridemia; pancreatitis